Hikma Pharmaceuticals Plc ADR (OP: HKMPY )

55.56 +3.86 (+7.47%)

Streaming Delayed Price Updated: 9:54 AM EDT, Aug 16, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	399
Open	54.00
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	51.70
Today's Range	54.00 - 55.56
52wk Range	42.23 - 55.75
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

January 08, 2024

From Guardant Health, Inc.

Via Business Wire

Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape

June 12, 2023

The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March. Methotrexate is an injected medication utilized to treat...

Via Benzinga

Performance

YTD	+22.30%	+22.30%
1 Month	+12.62%	+12.62%
3 Month	+11.59%	+11.59%
6 Month	+7.57%	+7.57%
1 Year	+5.89%	+5.89%

More News

Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

December 26, 2022

From Junshi Biosciences

Via GlobeNewswire

Friday Markets News

March 25, 2022

Via Talk Markets

Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)

August 27, 2021

From Bio-Thera Solutions, Ltd.

Via Business Wire

Summer Friday

June 25, 2021

Via Talk Markets

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.